CN101033467A - 奈瑟球菌基因组序列及其用法 - Google Patents

奈瑟球菌基因组序列及其用法 Download PDF

Info

Publication number
CN101033467A
CN101033467A CNA2007100037383A CN200710003738A CN101033467A CN 101033467 A CN101033467 A CN 101033467A CN A2007100037383 A CNA2007100037383 A CN A2007100037383A CN 200710003738 A CN200710003738 A CN 200710003738A CN 101033467 A CN101033467 A CN 101033467A
Authority
CN
China
Prior art keywords
sequence
protein
seq
nucleic acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007100037383A
Other languages
English (en)
Chinese (zh)
Inventor
M·皮扎
E·希基
J·彼得森
H·特特林
J·C·文特尔
V·马斯格阿尼
C·加莱奥蒂
M·莫拉
G·拉蒂
M·斯卡塞利
V·斯卡拉托
R·拉普奥利
C·M·弗拉泽
G·格兰迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUTE OF GENOMIC RESEARCH
Novartis Vaccines and Diagnostics Inc
Original Assignee
INSTITUTE OF GENOMIC RESEARCH
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/023573 external-priority patent/WO2000022430A2/en
Priority claimed from GB0004695A external-priority patent/GB0004695D0/en
Application filed by INSTITUTE OF GENOMIC RESEARCH, Chiron Corp filed Critical INSTITUTE OF GENOMIC RESEARCH
Publication of CN101033467A publication Critical patent/CN101033467A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2007100037383A 1999-04-30 2000-03-08 奈瑟球菌基因组序列及其用法 Pending CN101033467A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13206899P 1999-04-30 1999-04-30
US60/132,068 1999-04-30
PCT/US1999/023573 WO2000022430A2 (en) 1998-10-09 1999-10-08 Neisseria genomic sequences and methods of their use
USPCT/US99/23573 1999-10-08
GB0004695A GB0004695D0 (en) 2000-02-28 2000-02-28 Protein expression
GB0004695.3 2000-02-28
PCT/US2000/005928 WO2000066791A1 (en) 1999-04-30 2000-03-08 Neisseria genomic sequences and methods of their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN00809820A Division CN1359426A (zh) 1999-04-30 2000-03-08 奈瑟球菌基因组序列及其用法

Publications (1)

Publication Number Publication Date
CN101033467A true CN101033467A (zh) 2007-09-12

Family

ID=27255563

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007100037383A Pending CN101033467A (zh) 1999-04-30 2000-03-08 奈瑟球菌基因组序列及其用法
CN00809820A Pending CN1359426A (zh) 1999-04-30 2000-03-08 奈瑟球菌基因组序列及其用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN00809820A Pending CN1359426A (zh) 1999-04-30 2000-03-08 奈瑟球菌基因组序列及其用法

Country Status (13)

Country Link
US (1) US20070219347A1 (https=)
EP (2) EP1185691B1 (https=)
JP (1) JP2003527079A (https=)
CN (2) CN101033467A (https=)
AT (1) ATE430207T1 (https=)
AU (1) AU780308B2 (https=)
BR (1) BR0010361A (https=)
CA (1) CA2371032A1 (https=)
DE (1) DE60042114D1 (https=)
DK (1) DK1185691T3 (https=)
ES (1) ES2323845T3 (https=)
MX (1) MXPA01011047A (https=)
WO (1) WO2000066791A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110914441A (zh) * 2017-05-10 2020-03-24 环球生物能源公司 用于从3-甲基巴豆酸产生异丁烯的改进方法
CN113136444A (zh) * 2021-05-10 2021-07-20 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN116162140A (zh) * 2022-07-19 2023-05-26 四川大学华西医院 一种幽门螺杆菌重组抗原蛋白SecG及其制备方法与应用
WO2025077793A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP1149164A2 (en) 1999-01-22 2001-10-31 SmithKline Beecham Biologics SA Neisseria meningitidis polypeptides
EP1163343B1 (en) 1999-03-12 2009-12-09 GlaxoSmithKline Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NZ520445A (en) 2000-01-25 2004-02-27 Univ Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
RU2355704C2 (ru) * 2001-04-17 2009-05-20 Новартис Вэксинс Энд Диагностикс, Инк Моноклональное антитело, направленное против gna33 пептида, и его применение
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1495039A4 (en) 2002-03-20 2006-07-26 Univ Emory MUTANTS OF NEISSERIA, LIPOOLIGOSACCHARIDES AND IMMUNOGENIC COMPOSITIONS
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006096527A2 (en) * 2005-03-04 2006-09-14 Diversa Corporation Nucleic acids and proteins and methods for making and using them
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
US8039007B2 (en) 2006-06-29 2011-10-18 J. Craig Venter Institute, Inc. Polypeptides from Neisseria meningitidis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4735028A1 (en) 2023-06-30 2026-05-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047043A1 (en) * 1990-07-19 1992-01-20 Allen I. Oliff Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties
IE912559A1 (en) * 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
IL98839A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Vaccines comprising protein of the outer membrane of neisseria meningitidis
WO1998017805A2 (en) * 1996-10-24 1998-04-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office Invasion associated genes from neisseria meningitidis serogroup b
BR9914374A (pt) * 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110914441A (zh) * 2017-05-10 2020-03-24 环球生物能源公司 用于从3-甲基巴豆酸产生异丁烯的改进方法
CN113136444A (zh) * 2021-05-10 2021-07-20 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN113136444B (zh) * 2021-05-10 2024-04-19 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN116162140A (zh) * 2022-07-19 2023-05-26 四川大学华西医院 一种幽门螺杆菌重组抗原蛋白SecG及其制备方法与应用
WO2025077793A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Also Published As

Publication number Publication date
ATE430207T1 (de) 2009-05-15
EP1185691B1 (en) 2009-04-29
DE60042114D1 (de) 2009-06-10
AU3249200A (en) 2000-11-17
US20070219347A1 (en) 2007-09-20
MXPA01011047A (es) 2003-10-14
CN1359426A (zh) 2002-07-17
EP1605061A1 (en) 2005-12-14
AU780308B2 (en) 2005-03-17
ES2323845T3 (es) 2009-07-27
EP1185691A1 (en) 2002-03-13
WO2000066791A1 (en) 2000-11-09
BR0010361A (pt) 2003-06-10
DK1185691T3 (da) 2009-06-22
JP2003527079A (ja) 2003-09-16
CA2371032A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
CN101033467A (zh) 奈瑟球菌基因组序列及其用法
CN1224708C (zh) 脑膜炎奈瑟氏球菌抗原
CN1263854C (zh) 奈瑟球菌抗原
CN1338005A (zh) 奈瑟球菌基因组序列及其用途
JP6025675B2 (ja) 髄膜炎菌抗原および組成物
CN1617740A (zh) 抗沙眼衣原体的免疫
EP1562982B1 (en) Unexpected surface proteins in neisseria meningitidis
CN1433470A (zh) 奈瑟球菌的抗原性肽
CN1451046A (zh) 保守的奈瑟球菌抗原
CN1416352A (zh) 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
CN1636062A (zh) 编码多肽抗原的新肺炎链球菌可读框及其应用
CN1433471A (zh) 85kgDa奈瑟球菌的抗原
CN1911959A (zh) 奈瑟球菌基因组序列及其用途
RU2233328C2 (ru) Белок, полученный из neisseria meningitidis, проявляющий свойства антигена, антитело, нуклеиновая кислота (варианты) и содержащая их композиция
AU2005200246A1 (en) Neisseria genomic sequences and methods of their use
AU2004201096B2 (en) Neisseria genomic sequences and methods of their use
CN1824675A (zh) 奈瑟球菌抗原
AU2003235364B2 (en) Neisseria meningitidis antigens and compositions
US20050130917A1 (en) Gene expression during meningococcus adhesion
HK1033337B (en) Neisserial antigens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070912